Safety profile of mycophenolate mofetil

Safety profile of mycophenolate mofetil: a response

“…Drs Basara and Fauser's thoughful and insightful comments 1 reinforce what we have documented in our report, namely that mycophenolate mofetil (MMF) can be safely used for the treatment of chronic GVHD with few sideeffects occurring in a minority of the patients. 2 In our study, adverse gastrointestinal events including diarrhea, nausea and vomiting were the most common clinically relevant side-effects, occurring in 30% (five out of 15) of the patients, whereas severe liver toxicity occurred in one case.…”

Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies

“…16 Third, a previous study showed that a combination of CsA and mycophenolate mofetil had a more potent immunosuppressive effect than CsA and methotrexate in preventing graft rejection. 17 Basara et al, 18 reported that mycophenolate mofetil could be used safely and effectively for the prevention of acute GVHD. To enhance the effect of immunosuppression, mycophenolate mofetil was used on day 9 before transplantation.…”

Mycophenolate mofetil and cyclosporine for graft-versus-host disease prophylaxis following reduced intensity conditioning allogeneic stem cell transplantation

“…In this regard, the use of mycophenolate mofetil (MMF) for prophylaxis of aGVHD is rapidly increasing. [12][13][14][15][16][17][18] This report investigated the use of MMF/cyclosporin A (CsA) combination for GVHD prophylaxis in patients aged over 50 years receiving an HLA-identical sibling RIC allo-SCT.…”